Table 1

Demographics and baseline characteristics, intent-to-treat population

CharacteristicBimatoprost PF (N=302)Bimatoprost (N=295)
Age, years, mean (range)64.6 (29–91)65.0 (29–92)
Gender, male, n (%)132 (43.7)114 (38.6)
Race, n (%)
 Caucasian219 (72.5)206 (69.8)
 Black48 (15.9)55 (18.6)
 Hispanic29 (9.6)27 (9.2)
 Asian4 (1.3)5 (1.7)
 Other2 (0.7)2 (0.7)
Glaucoma medications requiring washout*
 All medications, n (%)235 (77.8)222 (75.3)
 Prostaglandin agonists, n (%)†195 (64.6)169 (57.3)
  Latanoprost103 (34.1)87 (29.5)
  Bimatoprost44 (14.6)42 (14.2)
  Travoprost48 (15.9)42 (14.2)
Iris colour, n (%)
 Dark187 (61.9)187 (63.4)
  Brown118 (39.1)113 (38.3)
  Dark brown43 (14.2)40 (13.6)
  Blue/grey-brown10 (3.3)19 (6.4)
  Green-brown15 (5.0)12 (4.1)
  Other dark1 (0.3)3 (1.0)
 Light114 (37.7)107 (36.3)
  Blue55 (18.2)48 (16.3)
  Blue-grey13 (4.3)17 (5.8)
  Grey2 (0.7)1 (0.3)
  Green12 (4.0)10 (3.4)
  Hazel31 (10.3)28 (9.5)
  Other light1 (0.3)3 (1.0)
 Dark/light‡1 (0.3)1 (0.3)
Diagnosis (both eyes), n (%)
 OHT105 (34.8)98 (33.2)
 Glaucoma197 (65.2)195 (66.1)
 OHT/glaucoma§0 (0.0)2 (0.7)
Mean IOP±SD, mm Hg, average of both eyes
 8:0024.53±2.2024.46±2.02
 10:0023.30±2.8523.26±2.61
 16:0022.31±2.9722.29±3.11
Baseline mean corneal thickness (worse eye), μm554.76554.46
  • *Other than prostaglandin analogues, IOP-lowering medications requiring washout included α-agonists, carbonic anhydrase inhibitors, β-adrenergic blocking agents and combination products.

  • †For latanoprost, bimatoprost and travoprost, based on total number of patients receiving prostaglandin agonists.

  • ‡One eye colour dark and one eye colour light.

  • §Patient with OHT in one eye and glaucoma in the other.

  • IOP, intraocular pressure; OHT, ocular hypertension; PF, preservative-free.